A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Retifanlimab (Primary)
- Indications Cervical cancer; Endometrial cancer; Non-small cell lung cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Acronyms POD1UM-101
- Sponsors Incyte Corporation; MacroGenics
- 11 Jun 2024 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Final results from the POD1UM-101 study (Cohort H, n=76) presented at the 48th European Society for Medical Oncology Congress.
- 16 Oct 2023 According to Incyte media release, final results from this study will be presented t the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.